

## AMENDMENTS TO THE CLAIMS

1. (currently amended): A method for decreasing the tumorigenicity or malignancy of a brain cancer cell, comprising altering the expression of ~~glycosylation of proteins produced by said cell, wherein said altered pattern of glycosylation is caused by the alteration of activity of~~ a glycosyltransferase within said cell wherein the glycosylation of proteins produced by said cell are altered.

2. (currently amended): ~~[[A]]~~ The method of claim 1 wherein said glycosyltransferase is selected from the group consisting of  $\alpha$ 2,3-ST glycosyltransferase,  $\alpha$ 2,6-ST glycosyltransferase, HexB glycosyltransferase, Fuco glycosyltransferase, GnTIII glycosyltransferase, GnTI glycosyltransferase, SLex-ST glycosyltransferase and GnTV glycosyltransferase.

3. (currently amended): ~~[[A]]~~ The method of claim ~~[[2]]~~ 1 wherein said brain cancer cell is a glioma cell.

4. (currently amended): ~~[[A]]~~ The method of claim ~~[[2]]~~ 1 wherein said brain cancer cell is a meningioma cell.

5. (canceled)

6. (canceled)

7. (currently amended): ~~[[A]]~~ The method of claim 3 wherein said altered expression of a glycosyltransferase activity is comprises increasing the expression of a glycosyltransferase ~~of glycosyltransferase is caused by the increase of activity of a glycosyltransferase~~ selected from the group consisting of 2,6-ST glycosyltransferase, Fuco glycosyltransferase, GnTI glycosyltransferase and GnTV glycosyltransferase.

8. (currently amended): [[A]] The method of claim 4 wherein said altered expression of a glycosyltransferase activity comprises increasing the expression of a glycosyltransferase ~~of glycosyltransferase is caused by the increase of activity of a glycosyltransferase~~ selected from the group consisting of SLex-ST glycosyltransferase and GnTV glycosyltransferase.

9. (canceled)

10. (canceled)

11. (currently amended): [[A]] The method of claim 7 wherein said increase in expression of a glycosyltransferase activity comprises ~~is caused by~~ the stable transfection of an exogenous DNA encoding for a glycosyltransferase, expressibly linked to an inducible promoter, into said cell wherein said exogenous DNA is selected from the group consisting of nucleic acid sequence encoding for 2,6-ST glycosyltransferase, Fuco glycosyltransferase, GnTI glycosyltransferase and GnTV glycosyltransferase.

12. (currently amended): [[A]] The method of claim 8 wherein said increase in expression of a glycosyltransferase activity comprises ~~is caused by~~ the stable transfection of an exogenous DNA encoding for a glycosyltransferase, expressibly linked to an inducible promoter, into said cell wherein said exogenous DNA is selected from the group consisting of nucleic acid sequence encoding for SLex-ST glycosyltransferase and GnTV glycosyltransferase.

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled).

19. (canceled)

20. (canceled)

21. (new): The method of claim 7, wherein said glycosyltransferase is  $\alpha$ 2,6-ST glycosyltransferase.

22. (new): The method of claim 21, wherein the brain cancer cell is in vivo.

23. (new): The method of claim 21, wherein the brain cancer cell is ex vivo.

24. (new): The method of claim 21, wherein the brain cancer cell is in vitro.

25. (new): The method of claim 11, wherein the exogenous DNA is nucleic acid encoding  $\alpha$ 2,6-ST glycosyltransferase.

26. (new): The method of claim 25, wherein the exogenous DNA is transfected in vivo.

27. (new): The method of claim 25, wherein the exogenous DNA is transfected ex vivo.

28. (new): The method of claim 25, wherein the exogenous DNA is transfected in vitro.

29. (new): The method of claim 25, wherein the exogenous DNA is an adenoviral vector encoding  $\alpha$ 2,6-ST glycosyltransferase.

30. (new): The method of claim 29, wherein the exogenous DNA is transfected in vivo.

31. (new): The method of claim 29, wherein the exogenous DNA is transfected ex vivo.

32. (new): The method of claim 29, wherein the exogenous DNA is transfected in vitro.

### AMENDMENTS TO THE DRAWINGS

The attached sheets of drawings include changes to Figures 1-38. These sheets, which include Figures 1-38, replace the original sheets including Figures 1-38. Only the lines, numbers, reference characters, and margins have been changed so that they comply with the rules and the comments on the Draftsperson's report. Therefore, no annotated sheets are included.

Attachment: Replacement Sheets 1-39